All data generated or analyzed during this study are included in the published articles.

Introduction {#sec005}
============

The incidence of perihilar cholangiocarcinoma (pCCA) is increasing stably \[[@pone.0232590.ref001]\], but the prognosis is generally poor \[[@pone.0232590.ref002], [@pone.0232590.ref003]\]. Surgical resection is the only potential way to achieve a long survival \[[@pone.0232590.ref003], [@pone.0232590.ref004]\], although only 20% patients are operable at diagnosis \[[@pone.0232590.ref005], [@pone.0232590.ref006]\]. However, the 5-year survival rates were reported to be 15\~40% \[[@pone.0232590.ref007]--[@pone.0232590.ref009]\], and the incidence of recurrence within two year was reported to be as high as 80% \[[@pone.0232590.ref010]\]. Positive bile duct margin is one of the most important factors for poor prognosis of pCCA after resection \[[@pone.0232590.ref011]--[@pone.0232590.ref013]\], and the incidence of a positive microscopic ductal margin (R1) ranged from 10\~72% \[[@pone.0232590.ref011], [@pone.0232590.ref013], [@pone.0232590.ref014]\]. Hence, additional resection is necessary to achieve a margin-negative (R0) resection and improved prognosis once R1 was confirmed by intraoperative frozen pathology.

However, additional resection of pCCA typically increased the risk of perioperative morbidity and mortality \[[@pone.0232590.ref014]--[@pone.0232590.ref016]\]. In addition, secondary R0 resection is hard to achieve in selected patients with more advanced disease and concurrent major vascular invasion \[[@pone.0232590.ref017], [@pone.0232590.ref018]\]. What's more, it remains controversial whether patients with pCCA could be benefited from additional resection \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017], [@pone.0232590.ref019]\], and to the best of our knowledge, no meta-analysis or randomized clinical trials (RCT) have been published on this issue. Hence, a meta-analysis was warranted to evaluate the clinical value of additional resection of intraoperative R1 for pCCA.

Material and method {#sec006}
===================

This study was based on published studies and the informed consent of the patients and the ethical approval were not required. This meta-analysis was conducted according to the preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Literature search {#sec007}
-----------------

A comprehensive search on the existing published medical literature was conducted by two independent researchers to investigate the outcomes of additional resection of intraoperative R1 for pCCA. English electronic databases such as PubMed, MedLine, Embase, the Cochrane Library, Web of Science were used to search the literature from Jan.1^st^ 2000 to Nov.30^th^ 2019. Key words were as follows: ("hilar cholangiocarcinoma" or "perihilar cholangiocarcinoma" or "Klatskin's tumor" or "HCCA" or "pCCA") AND ("additional resection" or "extensive resection" or "re-resection") AND ("margin"). The references of the included studies, relevant meta-analyses, reviews and guidelines were manually screened to look for potentially eligible studies.

Selection criteria {#sec008}
------------------

Inclusion criteria: i) patients with pCCA; ii) additional resection were conducted once R1 was confirmed by intraoperative frozen pathology; iii) comparison between secondary R0 and primary R0 or R1; iv) outcomes including overall survival (OS) rate; v) either randomized controlled trial (RCT) or retrospective studies.

Exclusion criteria: i) patients including non-pCCA; ii) data on the OS rates was not available; iii) grouping information was blur; ⅳ) studies based on overlapping cohorts deriving from the same center.

Intervention {#sec009}
------------

Hepatectomy with en-bloc total caudate lobe resection, and regional lymphadenectomy along with (+/−) vascular resection and reconstruction was conducted as a standard procedure for pCCA \[[@pone.0232590.ref004], [@pone.0232590.ref020]\], but the detailed procedure was different from each center \[[@pone.0232590.ref004], [@pone.0232590.ref020]\].

Both distal bile duct margin (DM) and proximal bile duct margin (PM) were collected to conduct an intraoperative frozen-section examination, and were evaluated by at least two pathologists within 30 min \[[@pone.0232590.ref021]\]. Of note, R1 was defined as microscopical positive ductal margin, including invasive carcinoma (R-inv) and carcinoma in situ (R-cis) \[[@pone.0232590.ref019]\].

Additional resection was performed when either DM or PM was positive. Additional resection typically involved extended hepatectomy and/or extirpation of the biliary tree, but the detailed procedure was different from each center \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017], [@pone.0232590.ref018]\].

Data extraction {#sec010}
---------------

Data such as the author's first name, year of publication, study methods, patient's characteristic, interventions, and outcomes were extracted and assessed by two independent investigators with predefined forms such as baseline characteristics and outcomes from each study. The odd ratios (ORs) of 1-, 3-, and 5-year OS were extracted directedly from the original data or extracted from the Kaplan-Meier curves according to the methods described in detail by Tierney et al \[[@pone.0232590.ref022]\]. and Parmar et al \[[@pone.0232590.ref023]\]. In case of disagreement, a third investigator intervened for a conclusion.

Quality assessment {#sec011}
------------------

The quality of non-randomized studies was assessed by the modified Newcastle-Ottawa Scale (NOS) \[[@pone.0232590.ref024]\], and more than 7 stars were defined as high quality, 4\~6 star as medium quality, and \<4 stars as low quality.

Statistical analysis {#sec012}
--------------------

The meta-analysis was registered at <http://www.crd.york.ac.uk/PROSPERO/> (Review registry 133971) and was performed using RevMan Version 5.3. ORs and 95%CIs were used to evaluate the 1-, 3-, and 5-year OS rates between secondary R0 and primary R0 or R1. Considering the inherent heterogeneity among the included studies, the pooled ORs for 1-, 3-, and 5-year OS rates were evaluated by the random-effects model \[[@pone.0232590.ref025]\]. But in the subgroup analysis, to choose whether random-effects or fixed-effects model was determined by heterogeneity test. The heterogeneity was assessed by the χ^2^ test and I^2^ statistics; P \< 0.10 or I^2^ \> 50% were considered as significant heterogeneity. When the hypothesis of homogeneity was rejected, the fixed-effects model was used to estimate the case with homogeneity, and the random-effects model was used for the cases with significant heterogeneity \[[@pone.0232590.ref026]\]. Sensitivity analysis was conducted as follows: one study at a time was removed and the remained were re-analyzed to determine whether the results could be affected significantly by single study \[[@pone.0232590.ref027]\]. Begg's and Egger's tests were used to evaluate publication bias using Stata 14.

Results {#sec013}
=======

Base characteristic of the included studies {#sec014}
-------------------------------------------

Initially, 388 records were identified by two independent reviewers. A total of 15 records were excluded after duplicate removal by NoteExpress 3.1. After browsing titles and abstracts, 29 records remained. And then, 19 records were excluded after full text review for the following reasons: i) two records for patients not pCCA \[[@pone.0232590.ref028], [@pone.0232590.ref029]\]; iii) 14 records for unclear grouping; ii) three records for data unavailable \[[@pone.0232590.ref021], [@pone.0232590.ref030], [@pone.0232590.ref031]\]. Among the remaining 10 records, one was excluded for letter \[[@pone.0232590.ref003], [@pone.0232590.ref032]\], and one for systematic review \[[@pone.0232590.ref003]\]. Finally, eight reports were enrolled for analysis \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017]--[@pone.0232590.ref019], [@pone.0232590.ref033]--[@pone.0232590.ref035]\], and all of them were non-RCTs. In total, 1275 patients were enrolled in this meta-analysis, including 179 patients in the secondary R0 group, 843 patients in the primary R0 group and 253 patients in the R1 group. The search strategies and results were shown in [Fig 1](#pone.0232590.g001){ref-type="fig"}.

![PRISMA flow diagram showing selection of articles for meta-analysis.](pone.0232590.g001){#pone.0232590.g001}

The characteristics and baseline demographic data of the patients in each research were listed in [Table 1](#pone.0232590.t001){ref-type="table"}, and the surgical procedure of additional resection were depicted in [Table 2](#pone.0232590.t002){ref-type="table"}.

10.1371/journal.pone.0232590.t001

###### Characteristics of the clinical trials included in the meta-analysis.

![](pone.0232590.t001){#pone.0232590.t001g}

  Study                                    Center                                        Study years   Preoperative biliary drainage   CA19-9 (U/ml)      Bismuth type (I II III/IV)   Differentiation (well/moderate poor)   Intraoperative Frozen analysis Method   Location                   Ductal resection margin status   Patients   MST (months)   Quality
  ---------------------------------------- --------------------------------------------- ------------- ------------------------------- ------------------ ---------------------------- -------------------------------------- --------------------------------------- -------------------------- -------------------------------- ---------- -------------- ---------
  Endo 2008 \[[@pone.0232590.ref034]\]     Memorial Sloan-Kettering Cancer Center, USA   1992--2005    79                              NA                 NA                           29/72                                  NA                                      Proximal duct              Primary R0                       54         56             7
  Secondary R0                             28                                            38                                                                                                                                                                                                                                                                 
  R1                                       19                                            32                                                                                                                                                                                                                                                                 
  Shingu 2010 \[[@pone.0232590.ref035]\]   Nagoya University School of Medicine, Japan   1979--2006    NA                              NA                 185/118                      96/207                                 H&E                                     Proximal duct              Primary R0                       275        NA             8
  Secondary R0                             8                                             NA                                                                                                                                                                                                                                                                 
  R1                                       20                                            NA                                                                                                                                                                                                                                                                 
  Ribero 2011 \[[@pone.0232590.ref014]\]   Umberto I hospital, Italy                     1989--2010    NA                              155(0.6--10721)    70/12                        14/78                                  H&E                                     Proximal duct              Primary R0                       54         29.2           8
  Secondary R0                             13                                            30.6                                                                                                                                                                                                                                                               
  R1                                       8                                             14.9                                                                                                                                                                                                                                                               
  Lee 2012\[[@pone.0232590.ref033]\]       Asan Medical Center, South korea              2000--2009    NA                              NA                 9/4                          4/9                                    NA                                      Proximal duct              Secondary R0                     7          NA             6
  R1                                       6                                             NA                                                                                                                                                                                                                                                                 
  Oguro 2015 \[[@pone.0232590.ref013]\]    National Cancer Center Hospital, Japan        2000--2011    134                             64(0--256800)      134/90                       53/171                                 H&E                                     Proximal duct              Primary R0                       149        56.6           8
  Secondary R0                             43                                            29.4                                                                                                                                                                                                                                                               
  R1                                       32                                            21.5                                                                                                                                                                                                                                                               
  Ma 2018 \[[@pone.0232590.ref017]\]       West China Hospital, China                    2000--2017    174                             195.6(5--1000)     123/105                      16/212                                 NA                                      Proximal duct              Primary R0                       175        23.00          8
  Secondary R0                             21                                            20.99                                                                                                                                                                                                                                                              
  R1                                       32                                            11.60                                                                                                                                                                                                                                                              
  Zhang 2018 \[[@pone.0232590.ref019]\]    Multi-center, USA                             2000--2014    211                             132(44.0--360.7)   177/58                       44/194                                 NA                                      Proximal and distal duct   Primary R0                       136        22.3           8
  Secondary R0                             29                                            30.6                                                                                                                                                                                                                                                               
  R1                                       92                                            18.5                                                                                                                                                                                                                                                               
  Otsuka 2019 \[[@pone.0232590.ref018]\]   Nagoya University Hospital, Japan             2001--2015    71                              NA                 NA                           22/52                                  NA                                      Distal duct                Secondary R0                     30         NA             7
  R1                                       44                                            NA                                                                                                                                                                                                                                                                 

NA, not available; CA19-9, carcinoma antigen 19--9; H&E, haematoxylin and eosin staining; MST, median survival time.

10.1371/journal.pone.0232590.t002

###### Surgical procedures of included studies.

![](pone.0232590.t002){#pone.0232590.t002g}

  Study                               Endo 2008 \[[@pone.0232590.ref034]\]   Shingu 2010 \[[@pone.0232590.ref035]\]   Ribero 2011 \[[@pone.0232590.ref014]\]   Lee 2012 \[[@pone.0232590.ref033]\]   Oguro 2015 \[[@pone.0232590.ref013]\]   Ma 2018 \[[@pone.0232590.ref017]\]   Zhang 2018 \[[@pone.0232590.ref019]\]   Otsuka 2019 \[[@pone.0232590.ref018]\]
  ----------------------------------- -------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------- --------------------------------------- ------------------------------------ --------------------------------------- ----------------------------------------
  Bile duct resection only            NA                                     15                                       7                                        30                                    NA                                      NA                                   56                                      44
  Left hepatectomy                    83                                     107                                      30                                       27                                    97                                      120                                  63                                      21
  Left trisectionectomy               43                                     3                                        13                                       25                                    7                                       37                                   9                                       
  Mesohepatectomy                     6                                      1                                        3                                        2                                     39                                      NA                                   NA                                      
  Right hepatectomy                   100                                    13                                       65                                       95                                    49                                      34                                   33                                      
  Right trisectionectomy              12                                     26                                       19                                       5                                     13                                      64                                   8                                       
  Other hepatectomies                 20                                     2                                        13                                       NA                                    NA                                      NA                                   NA                                      
  Combined caudate lobe resection     36                                     268                                      NA                                       NA                                    NA                                      NA                                   90                                      NA
  Combined pancreatoduodenectomy      NA                                     28                                       2                                        3                                     13                                      NA                                   3                                       9
  Combined portal vein resection      9                                      87                                       20                                       9                                     46                                      57                                   NA                                      20
  Combined hepatic artery resection   NR                                     32                                       2                                        3                                     21                                      32                                   NA                                      7

NA, not available.

Methodological quality of the included studies {#sec015}
----------------------------------------------

The quality of each included research was shown in [Table 1](#pone.0232590.t001){ref-type="table"}. Seven researches were assessed be of high quality \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017]--[@pone.0232590.ref019], [@pone.0232590.ref034], [@pone.0232590.ref035]\], and one were of medium quality \[[@pone.0232590.ref033]\].

Primary endpoint {#sec016}
----------------

The 1-, 3-, and 5-year OS rates comparing between secondary R0 group and primary R0 group were evaluated in six included studies \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017], [@pone.0232590.ref019], [@pone.0232590.ref034], [@pone.0232590.ref035]\]. The pooled OR for the 1-, 3-, and 5-year OS rate between secondary R0 group and primary R0 group were 1.03(95%CI 0.64\~1.67, P = 0.90, [Fig 2A](#pone.0232590.g002){ref-type="fig"}), 0.92(95%CI 0.52\~1.64, P = 0.78, [Fig 2B](#pone.0232590.g002){ref-type="fig"}), and 0.83(95%CI 0.37\~1.84, P = 0.65, [Fig 2C](#pone.0232590.g002){ref-type="fig"}), respectively.

![Forest plot of overall survival rates between secondary R0 group and primary R0 group.\
(A). 1-year overall survival rate. (B). 3-year overall survival rate. (C). 5-year overall survival rate.](pone.0232590.g002){#pone.0232590.g002}

The 1-, 3-, and 5-year OS rates comparing between secondary R0 group and R1 group were evaluated in eight included studies \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017]--[@pone.0232590.ref019], [@pone.0232590.ref033]--[@pone.0232590.ref035]\]. The pooled OR for the 1-, 3-, and 5-year OS rate between secondary R0 group and R1 group were 2.14(95%CI 1.31\~3.50, P = 0.002, [Fig 3A](#pone.0232590.g003){ref-type="fig"}), 2.58(95%CI 1.28\~5.21, P = 0.008, [Fig 3B](#pone.0232590.g003){ref-type="fig"}), and 3.54(95%CI 1.67\~7.50, P = 0.001, [Fig 3C](#pone.0232590.g003){ref-type="fig"}), respectively.

![Forest plot of the overall survival rates between secondary R0 group and R1 group.\
(A). 1-year overall survival rate. (B). 3-year overall survival rate. (C). 5-year overall survival rate.](pone.0232590.g003){#pone.0232590.g003}

Subgroup analysis stratified by the West and the East {#sec017}
-----------------------------------------------------

A total of three researches from the West were included in this meta-analysis \[[@pone.0232590.ref014], [@pone.0232590.ref019], [@pone.0232590.ref034]\], including two from the USA \[[@pone.0232590.ref019], [@pone.0232590.ref034]\] and one from Italy \[[@pone.0232590.ref014]\]. The pooled OR for the 1-, and 3-year OS rate between secondary R0 group and primary R0 group were 1.19(95%CI 0.58\~2.44, P = 0.64, [Table 3](#pone.0232590.t003){ref-type="table"}), 1.00(95%CI 0.57\~1.78, P = 0.99, [Table 3](#pone.0232590.t003){ref-type="table"}), respectively. And, the pooled OR for the 1-, and 3-year OS rate between secondary R0 group and R1 group were 2.05(95%CI 0.95\~4.41, P = 0.07, [Table 3](#pone.0232590.t003){ref-type="table"}), 1.91(95%CI 0.96\~3.81, P = 0.07, [Table 3](#pone.0232590.t003){ref-type="table"}), respectively.

10.1371/journal.pone.0232590.t003

###### Subgroup analysis stratified by the West and the East.

![](pone.0232590.t003){#pone.0232590.t003g}

  Subgroup                                Studies included   Overall Survival                               
  --------------------------------------- ------------------ ------------------ -------- ------------------ -------------
  The West, Secondary R0 vs. Primary R0                                                                     
  1-year                                  3                  314                Fixed    1.19(0.58--2.44)   0.64
  3-year                                  3                  314                Fixed    1.00(0.57--1.78)   0.99
  The East, Secondary R0 vs. Primary R0                                                                     
  1-year                                  5                  671                Fixed    0.94(0.43--2.02)   0.87
  3-year                                  5                  671                Random   0.66(0.38--1.16)   0.15
  The West, Secondary R0 vs. R1                                                                             
  1-year                                  3                  189                Fixed    2.05(0.95--4.41)   0.07
  3-year                                  3                  189                Fixed    1.91(0.96--3.81)   0.07
  The East, Secondary R0 vs. R1                                                                             
  1-year                                  5                  243                Fixed    2.19(1.18--4.07)   **0.01**
  3-year                                  5                  243                Fixed    3.21(1.75--5.89)   **\<0.001**

A total of five researches from the East were included in this meta-analysis \[[@pone.0232590.ref013], [@pone.0232590.ref017], [@pone.0232590.ref018], [@pone.0232590.ref033], [@pone.0232590.ref035]\], including three from Japan \[[@pone.0232590.ref013], [@pone.0232590.ref018], [@pone.0232590.ref035]\], one from South Korea \[[@pone.0232590.ref033]\], and one from China \[[@pone.0232590.ref017]\]. The pooled OR for the 1-, and 3-year OS rate between secondary R0 group and primary R0 group were 0.94(95%CI 0.43\~2.02, P = 0.87, [Table 3](#pone.0232590.t003){ref-type="table"}), 0.66(95%CI 0.38\~1.16, P = 0.15, [Table 3](#pone.0232590.t003){ref-type="table"}), respectively. And, the pooled OR for the 1-, and 3-year OS rate between secondary R0 group and R1 group were 2.19(95%CI 1.18\~4.07, P = 0.01, [Table 3](#pone.0232590.t003){ref-type="table"}), 3.21(95%CI 1.75\~5.89, P\<0.001, [Table 3](#pone.0232590.t003){ref-type="table"}), respectively.

Prognostic factors for pCCA after resection {#sec018}
-------------------------------------------

Prognostic factors were analyzed in six studies using univariate and multivariate analysis \[[@pone.0232590.ref013], [@pone.0232590.ref017], [@pone.0232590.ref019], [@pone.0232590.ref033]--[@pone.0232590.ref035]\]. Tumor differentiation, lymph node involvement, combined PV and/or HA, microscopic venous invasion, microscopic liver invasion, and tumor stage were confirmed to be independent risk factors of overall survival. Details were depicted in [Table 4](#pone.0232590.t004){ref-type="table"}.

10.1371/journal.pone.0232590.t004

###### Meta-analysis of prognostic factors for pCCA after resection.

![](pone.0232590.t004){#pone.0232590.t004g}

  Prognostic factors                                                        Studies included   Heterogeneity   Hazard ratio   95%CI   
  ------------------------------------------------------------------------- ------------------ --------------- -------------- ------- ------------
  Tumour differentiation (others versus well differentiated)                6                  0               0.51           2.25    1.82--2.79
  Lymph node involvement (yes versus no)                                    6                  0               0.83           1.85    1.55--2.21
  Combined PV and/or HA (yes versus no)                                     3                  37              0.21           1.37    1.11--1.69
  Microscopic perineural invasion (yes versus no)                           3                  66              0.05           1.59    0.94--2.68
  Microscopic venous invasion (yes versus no)                               2                  0               0.98           1.42    1.08--1.86
  Microscopic liver invasion (yes versus no)                                2                  0               0.46           1.43    1.08--1.90
  Tumour status (T3+T4 versus T1+T2)[\*](#t004fn002){ref-type="table-fn"}   2                  0               0.43           1.23    1.02--1.46

PA, portal vein resection; HA, hepatic artery resection;

\*according to the 8^th^ edition American Joint Committee on Cancer (AJCC) staging guidelines.

Sensitivity analysis and publication bias {#sec019}
-----------------------------------------

Removal of any individual study did not affect the overall outcome of this meta-analysis significantly in the sensitivity analysis. Significant publication bias was not observed in the pooled OR for 1-, 3-, and 5-year OS between secondary R0 and primary R0/R1 (all P \>0.05, [Fig 4](#pone.0232590.g004){ref-type="fig"}).

![Publication bias in this study.\
(A). 1-year overall survival rate between secondary R0 group and primary R0 group. (B). 3-year overall survival rate between secondary R0 group and primary R0 group. (C.) 5-year overall survival rate between secondary R0 group and primary R0 group. (D). 1-year overall survival rate between secondary R0 group and R1 group. (E). 3-year overall survival rate between secondary R0 group and R1 group. (F). 5-year overall survival rate between secondary R0 group and R1 group.](pone.0232590.g004){#pone.0232590.g004}

Discussion {#sec020}
==========

This was the first meta-analysis that evaluated the clinical value of additional resection of intraoperative R1 for pCCA. A total of 8 studies with 1275 patients were included in this meta-analysis. Results showed that the 1-, 3-, and 5-year OS rates were comparable between patients with secondary R0 and patients with primary R0, but both are better than patients with R1. Hence, additional resection for pCCA was recommended in case of intraoperative R1 to achieve a better prognosis, especially in selected patients.

R0 resection is a standard procedure for curative pCCA, although the detailed procedures are different from each other worldwide \[[@pone.0232590.ref004], [@pone.0232590.ref036]--[@pone.0232590.ref038]\]. But the incidence of R1 was as high as 10\~72% \[[@pone.0232590.ref011], [@pone.0232590.ref013], [@pone.0232590.ref014]\], mainly due to the complex anatomy of hepatic hilar and biological characteristics of pCCA. And, patients with R1 had a poor prognosis \[[@pone.0232590.ref011]--[@pone.0232590.ref013]\]. In this meta-analysis, the initial R1 ranged from 12.3% to 37.2%. Hence, additional resection of intraoperative pathologic R1 for pCCA is necessary to achieve a better prognosis. However, it remains controversial whether additional resection could benefit the patients with intraoperative R1 in the view of long-term prognosis \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017], [@pone.0232590.ref019]\]. In this meta-analysis, we found that the 1-, 3-, and 5-year OS rates in the secondary R0 group were higher than those in the R1 group, but the median survival time (MST) in the primary R0, secondary R0, and R1 were 22.3--56.6 months, 20.99--38 months, and 11.60--32 months, respectively. Hence, the conclusion that patients with intraoperative pathologic R1 would be benefited from additional resection needed further validation.

However, not all patients with intraoperative R1 would be benefited from resection. Major differences were found in patient characteristics and treatment strategies between the East and the West pCCA cohorts \[[@pone.0232590.ref039]\]. In the subgroup of the West, there were no significant difference in the pooled OR for the 1- and 3- year OS of patients between secondary R0 group and R1 group, which suggested that additional resection would not benefit patients in the West. Reasons might be as follows: 1) epidemiology of pCCA was greatly different between the West and East, the incidence of pCCA was much higher in the East than that in the West \[[@pone.0232590.ref040]\]. What's more, liver fluke was the leading etiology of pCCA in the East while it was primary sclerosing cholangitis in the West \[[@pone.0232590.ref040]\]; 2) cirrhosis was an important factor of decision-making on hepatectomy, which was much more frequent and serious in the East \[[@pone.0232590.ref039]\]; 3) pCCA patients were typically present with obstructive jaundice, and endoscopic biliary drainage was found to be associated with improved prognosis compared with percutaneous biliary drainage, which was conducted much more frequently in the East \[[@pone.0232590.ref041]\]; 4) preoperative portal vein embolization was repeatedly confirmed to be able to improve the prognosis of pCCA via increasing the future remnant liver volume, which was also performed much often in the East \[[@pone.0232590.ref042], [@pone.0232590.ref043]\]; 4) surgical techniques including vascular reconstruction, and lymph node dissection have been conducted prevalently in Japan, South Korea, and China without increased risk of severe postoperative complications \[[@pone.0232590.ref039]\].

In an attempt to achieve a secondary R0, more extensive resection would be proposed, which would increase the risk of morbidity and mortality in turn. Liver failure, biliary fistula, anastomotic leak, surgical site infection, intra-abdominal bleeding, and vascular complications are the common complications related to additional resection, and the morbidity ranged from 40\~71.2% \[[@pone.0232590.ref019], [@pone.0232590.ref044]\]. The procedure related postoperative mortality varied from 2 to 15% \[[@pone.0232590.ref045], [@pone.0232590.ref046]\], although it was reported to be decreased \[[@pone.0232590.ref009]\]. Additional resection should better be conducted in highly experienced centers if future remnant liver volume was adequate and additional resection was feasible in anatomy, but data on morbidity and mortality was unavailable in most of the included studies. In addition, considering that the longitudinal infiltration of pCCA along the bile duct was confirmed to be 4.6mm\~14.0mm \[[@pone.0232590.ref047]\], minor additional resection was recommended in case of intraoperative R1, on condition that a secondary R0 was guaranteed.

As is known to all, one size does not fit for all. R1 typical includes R-inv and R-cis, and R-inv is much more aggressive than R-cis in pathology theoretically \[[@pone.0232590.ref003], [@pone.0232590.ref029]\]. However, recent studies showed that addition resection could not improve the prognosis of extrahepatic cholangiocarcinoma patients with initial R-cis \[[@pone.0232590.ref018], [@pone.0232590.ref048]\]. In our newly published meta-analysis, no significant differences were observed in the 1-, 2-, and 3-year survival rates between groups of R0 and R-cis (all P\>0.05), both of which were significantly higher than those in the group of R-inv (all P\<0.05) \[[@pone.0232590.ref049]\], which indicated that additional resection would be not necessary for patients with initial R-cis. Unfortunately, relevant data was unable to extract in the included studies, and further studies are badly needed on this issue.

Intraoperative frozen section analysis is prevalently used to assess resection margins during cancer surgery, and is a determinant whether addition resection is warranted to achieve R0 \[[@pone.0232590.ref050], [@pone.0232590.ref051]\]. But the clinical value of intraoperative frozen section in pCCA was limited, because the sensitivity was reported to be only 68% \[[@pone.0232590.ref021]\]. The inconsistency between frozen section and permanent histopathological analyses of bile ductal margin might be explained by as follows: 1) the biological characteristics of pCCA, because pCCA often spread longitudinally along the axis of the bile duct, partially in the submucosal space with wide invasion to the perilymph, perineural and perivasculature \[[@pone.0232590.ref052]\], which increased the risk of sampling errors; 2) the presence of atypical cells within the boundary zone between the tumor and the normal duct epithelium \[[@pone.0232590.ref034]\]; 3) unrecognized margin due to energy surgical instruments such as CUSA, Endo-GIA and so on. However, intraoperative R1 could put the surgeons into a dilemma because additional resection increased the risk of morbidity or was sometimes impossible anatomically.

There were several restrictions of this meta-analysis. First, all the included studies were retrospective studies, indicating an apparent recalling bias and selection bias. Secondly, major differences were found in pCCA between the West and the East, and the results of subgroup analysis were indeed different. Thirdly, the procedures of radical resection for pCCA were different from different countries \[[@pone.0232590.ref013], [@pone.0232590.ref014], [@pone.0232590.ref017], [@pone.0232590.ref019]\]. Fourth, the safety of addition resection was not evaluated because postoperative morbidity and mortality was only reported in one study. Fifth, right or left hepatectomy was depended on the Bismuth-Corlette type, which would be affected the prognosis of pCCA, but the data was unavailable. Sixth, margin status including either R-inv or R-cis was the key, but relevant subgroup analysis was unable to conduct due to insufficient data. The last but not the least, publication bias was hard to be avoided, although significant publication bias was not observed in the study.

Conclusion {#sec021}
==========

With the current data, we concluded that additional resection should be recommended in selected patients with intraoperative R1, especially in highly experienced centers. However, the standard procedure of radical resection for pCCA and a higher sensitivity and specificity margin examining are badly needed in clinical. In addition, further studies concerning on the types of R1 are also needed.

Supporting information {#sec022}
======================

###### Checklist_PRISMA.

(DOC)

###### 

Click here for additional data file.

###### Search strategy in PubMed.
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HCCA

:   hilar cholangiocarcinoma

pCCA

:   perihilar cholangiocarcinoma

OS

:   overall survival

OR

:   Odds ratio

CI

:   confidence interval

RCT

:   randomized controlled trial

PA

:   portal vein resection

HA

:   hepatic artery resection

PM

:   proximal bile duct margin

DM

:   distal bile duct margin
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